Volume 30; Issue 12

Main
Annals of Oncology
Volume 30; Issue 12

Annals of Oncology

Volume 30; Issue 12

1

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, N, Lepage, P, Coutzac, C, Soularue, E, Le Roux, K, Monot, C, Boselli, L, Routier, E, Cassard, L, Collins, M, Vaysse, T, Marthey, L, Eggermont, A, Asvatourian, V, Lanoy, E, Mateus, C, Robert, C

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 142 KB

english, 2019

2

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

Park, J H, Jonas, S F, Bataillon, G, Criscitiello, C, Salgado, R, Loi, S, Viale, G, Lee, H J, Dieci, M V, Kim, S -B, Vincent-Salomon, A, Curigliano, G, André, F, Michiels, S

Journal:

Annals of Oncology

Year:

2019

Language:

english

File:

PDF, 615 KB

english, 2019

3

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, N, Lepage, P, Coutzac, C, Soularue, E, Le Roux, K, Monot, C, Boselli, L, Routier, E, Cassard, L, Collins, M, Vaysse, T, Marthey, L, Eggermont, A, Asvatourian, V, Lanoy, E, Mateus, C, Robert, C

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 142 KB

2019

4

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy

Park, J H, Jonas, S F, Bataillon, G, Criscitiello, C, Salgado, R, Loi, S, Viale, G, Lee, H J, Dieci, M V, Kim, S -B, Vincent-Salomon, A, Curigliano, G, André, F, Michiels, S

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 615 KB

2019

5

Clinical relevance of TNM staging system according to breast cancer subtypes

Park, Y.H., Lee, S.J., Cho, E.Y., La. Choi, Y., Lee, J.E., Nam, S.J., Yang, J.-H., Shin, J.H., Ko, E.Y., Han, B.-K., Ahn, J.S., Im, Y.-H.

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 79 KB

2019

6

Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial

Yoon, H.H., Bendell, J.C., Braiteh, F.S., Firdaus, I., Philip, P.A., Cohn, A.L., Lewis, N., Anderson, D.M., Arrowsmith, E., Schwartz, J.D., Gao, L., Hsu, Y., Xu, Y., Ferry, D., Alberts, S.R., Wainberg

Journal:

Annals of Oncology

Year:

2019

File:

PDF, 74 KB

2019